Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 0.79 |
| ▸ | ACACA | Q13085 | 14/20 | 0.79 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182583 | 0.91 | ACACB (0.75) | ACACBACACAKDM2BGAA | |
| SCHEMBL977942 | 0.89 | ACACB (1.00) | ACACBACACAKDM4ELMNAKDM2B | |
| SCHEMBL3465044 | 0.89 | ACACB (1.00) | ACACBACACAKDM4ELMNAKDM2B | |
| SCHEMBL3462988 | 0.89 | ACACB (1.00) | ACACBACACAKDM4ELMNAKDM2B | |
| SCHEMBL6184783 | 0.88 | ACACB (0.67) | ACACBACACACCR5KCNH2KDM2B | |
| SCHEMBL6182631 | 0.88 | ACACB (0.84) | ACACBACACAKDM4ELMNAKDM2B | |
| SCHEMBL6181355 | 0.88 | ACACB (0.94) | ACACBACACAKDM4ELMNAKDM2B | |
| SCHEMBL975322 | 0.86 | ACACB (0.69) | ACACBACACAKDM2BGAA | |
| SCHEMBL6182512 | 0.85 | ACACB (0.80) | ACACBACACAKDM2BGAA | |
| SCHEMBL6181768 | 0.85 | ACACB (0.79) | ACACBACACAKDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | claimed |
| US-20110003767-A1 | Inhibitors of Acetyl-CoA Carboxylase for Treatment of Neuronal Hypometabolism | NEUERA PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| EP-2150265-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | Neuera Pharmaceuticals, Inc. (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008140828-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | ACCERA, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-6979741-B2 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003767-A1 | Inhibitors of Acetyl-CoA Carboxylase for Treatment of Neuronal Hypometabolism | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885CCR5 4267/4885 |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885CCR5 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.